Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)

NCT04674761 is registered in ClinicalTrials.gov with Albireo as lead sponsor.

NCT NCT04674761
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04674761 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)
Lead sponsor
Albireo
Phase
Phase 3
Overall status
Completed
Start date
March 19, 2021
Completion date
September 9, 2022
Enrollment
52 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome